Search Results - "van Putten, L J"

Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value by Abbas, Saman, Lugthart, Sanne, Kavelaars, François G., Schelen, Anita, Koenders, Jasper E., Zeilemaker, Annelieke, van Putten, Wim J.L., Rijneveld, Anita W., Löwenberg, Bob, Valk, Peter J.M.

“…Somatic mutations in isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) were recently demonstrated in acute myeloid leukemia (AML), but their prevalence and…”
Get full text

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy by Wortman, B. G., Creutzberg, C. L., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C. H. W., van der Steen-Banasik, E. M., Mens, J. W. M., Slot, A., Kroese, M. C. Stenfert, van Triest, B., Nijman, H. W., Stelloo, E., Bosse, T., de Boer, S. M., van Putten, W. L. J., Smit, V. T. H. B. M, Nout, R. A.

“…Background PORTEC-2 was a randomised trial for women with high-intermediate risk (HIR) endometrial cancer, comparing pelvic external beam radiotherapy (EBRT)…”
Get full text

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial by Vellenga, Edo, van Putten, Wim L.J., van 't Veer, Mars B., Zijlstra, Josée M., Fibbe, Willem E., van Oers, Marinus H.J., Verdonck, Leo F., Wijermans, Pierre W., van Imhoff, Gustaaf W., Lugtenburg, Pieternella J., Huijgens, Peter C.

“…We evaluated the role of rituximab during remission induction chemotherapy in relapsed aggressive CD20+ non-Hodgkin lymphoma. Of 239 patients, 225 were…”
Get full text

High‐dose Ara‐C and beam with autograft rescue in R‐CHOP responsive mantle cell lymphoma patients by Van’t Veer, Mars B., De Jong, Daphne, MacKenzie, Marius, Kluin‐Nelemans, Hanneke C., Van Oers, Marinus H. J., Zijlstra, Jose, Hagenbeek, Anton, Van Putten, Wim L. J.

“…Summary Mantle cell lymphoma (MCL) has a dismal outcome when treated with conventional chemotherapy. This single arm phase 2 study evaluated intensive…”
Get full text

Monosomal Karyotype in Acute Myeloid Leukemia: A Better Indicator of Poor Prognosis Than a Complex Karyotype by BREEMS, Dimitri A, VAN PUTTEN, Wim L. J, LOWENBERG, Bob, DE GREEF, Georgine E, VAN ZELDEREN-BHOLA, Shama L, GERSSEN-SCHOORL, Klasien B. J, MELLINK, Clemens H. M, NIEUWINT, Aggie, JOTTERAND, Martine, HAGEMEIJER, Anne, BERNA BEVERLOO, H

“…To investigate the prognostic value of various cytogenetic components of a complex karyotype in acute myeloid leukemia (AML). Cytogenetics and overall survival…”
Get full text

Autologous bone marrow transplantation as consolidation therapy in the treatment of adult patients under 60 years with acute myeloid leukaemia in first complete remission: a prospective randomized Dutch–Belgian Haemato‐Oncology Co‐operative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) trial by Breems, Dimitri A., Boogaerts, Marc A., Dekker, Adriaan W., Van Putten, Wim L. J., Sonneveld, Pieter, Huijgens, Peter C., Van der Lelie, Johannes, Vellenga, Edo, Gratwohl, Alois, Verhoef, Gregor E. G., Verdonck, Leo F., Löwenberg, Bob

“…Summary The question as to whether autologous stem cell transplantation (SCT) after consolidation chemotherapy improves the probability of survival of patients…”
Get full text

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? by Cornelissen, Jan J., van Putten, Wim L.J., Verdonck, Leo F., Theobald, Matthias, Jacky, Emanuel, Daenen, Simon M.G., van Marwijk Kooy, Marinus, Wijermans, Pierre, Schouten, Harry, Huijgens, Peter C., van der Lelie, Hans, Fey, Martin, Ferrant, Augustin, Maertens, Johan, Gratwohl, Alois, Lowenberg, Bob

“…The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome…”
Get full text

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years by Cornelissen, J J, Versluis, J, Passweg, J R, van Putten, W L J, Manz, M G, Maertens, J, Beverloo, H B, Valk, P J M, van Marwijk Kooy, M, Wijermans, P W, Schaafsma, M R, Biemond, B J, Vekemans, M-C, Breems, D A, Verdonck, L F, Fey, M F, Jongen-Lavrencic, M, Janssen, J J W M, Huls, G, Kuball, J, Pabst, T, Graux, C, Schouten, H C, Gratwohl, A, Vellenga, E, Ossenkoppele, G, Löwenberg, B

“…The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued…”
Get full text

Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer by Foekens, J A, Look, M P, Peters, H A, van Putten, W L, Portengen, H, Klijn, J G

“…Urokinase-type plasminogen activator (uPA) is a proteolytic enzyme thought to be involved in processes leading to tumor cell invasion of surrounding tissues…”
Get more information

Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON‐SAKK co‐operative group studies by De Greef, Georgine E., Van Putten, Wim L. J., Boogaerts, Marc, Huijgens, Peter C., Verdonck, Leo F., Vellenga, Edo, Theobald, Matthias, Jacky, Emanuel, Löwenberg, Bob

“…Summary Complete remission (CR) in patients with acute myeloid leukaemia (AML) is the primary endpoint for the evaluation of induction treatment and treatment…”
Get full text

Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers by Rockova, Veronika, Abbas, Saman, Wouters, Bas J., Erpelinck, Claudia A.J., Beverloo, H. Berna, Delwel, Ruud, van Putten, Wim L.J., Löwenberg, Bob, Valk, Peter J.M.

“…Numerous molecular markers have been recently discovered as potential prognostic factors in acute myeloid leukemia (AML). It has become of critical importance…”
Get full text

Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories by CORNELISSEN, Jan J, BREEMS, Dimitri, BIEMOND, Bart J, VELLENGA, Edo, VERDONCK, Leo F, OSSENKOPPELE, Gert J, LÖWENBERG, Bob, PUTTEN, Wim L. J. Van, GRATWOHL, Alois A, PASSWEG, Jakob R, PABST, Thomas, MAERTENS, Johan, BERNA BEVERLOO, H, VAN MARWIJK KOOY, Marinus, WIJERMANS, Pierre W

“…To determine to what extent allogeneic hematopoietic stem-cell transplantation (alloHSCT) quantitatively reduces relapse in acute myeloid leukemia with…”
Get full text

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio by Versluis, J, in ‘t Hout, F E M, Devillier, R, van Putten, W L J, Manz, M G, Vekemans, M -C, Legdeur, M -C, Passweg, J R, Maertens, J, Kuball, J, Biemond, B J, Valk, P J M, van der Reijden, B A, Meloni, G, Schouten, H C, Vellenga, E, Pabst, T, Willemze, R, Löwenberg, B, Ossenkoppele, G, Baron, F, Huls, G, Cornelissen, J J

“…Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We…”
Get full text

Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction by Kerkhoffs, Jean‐Louis H., Van Putten, Wim L. J., Novotny, Viera M. J., Te Boekhorst, Peter A.W., Schipperus, Martin R., Zwaginga, Jaap Jan, Van Pampus, Lizzy C. M., De Greef, Georgine E., Luten, Marleen, Huijgens, Peter C., Brand, Anneke, Van Rhenen, Dick J.

“…Summary Pathogen reduction (PR) of platelet products increases costs and available clinical studies are equivocal with respect to clinical and haemostatic…”
Get full text

Update of Dutch Multicenter Dose-Escalation Trial of Radiotherapy for Localized Prostate Cancer by Al-Mamgani, Abrahim, M.D, van Putten, Wim L.J., M.Sc, Heemsbergen, Wilma D., Ph.D, van Leenders, Geert J.L.H., M.D., Ph.D, Slot, Annerie, M.D, Dielwart, Michel F.H., M.D, Incrocci, Luca, M.D., Ph.D, Lebesque, Joos V., M.D., Ph.D

“…Purpose To update the analysis of the Dutch dose-escalation trial of radiotherapy for prostate cancer. Patients and Methods A total of 669 patients with…”
Get full text

Intensified alemtuzumab–CHOP therapy for peripheral T-cell lymphoma by Kluin-Nelemans, H.C., van Marwijk Kooy, M., Lugtenburg, P.J., van Putten, W.L.J., Luten, M., Oudejans, J., van Imhoff, G.W.

“…The prognosis of T-cell lymphoma is poor. To explore the addition of the monoclonal antibody alemtuzumab, we studied the efficacy and tolerability of an…”
Get full text

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis by Versluis, Jurjen, MD, Hazenberg, Carin L E, MD, Passweg, Jakob R, Prof, van Putten, Wim L J, MSc, Maertens, Johan, Prof, Biemond, Bart J, MD, Theobald, Matthias, Prof, Graux, Carlos, Prof, Kuball, Jurgen, Prof, Schouten, Harry C, Prof, Pabst, Thomas, Prof, Löwenberg, Bob, Prof, Ossenkoppele, Gert, Prof, Vellenga, Edo, Prof, Cornelissen, Jan J, Prof

“…Summary Background Acute myeloid leukaemia mainly affects elderly people, with a median age at diagnosis of around 70 years. Although about 50–60% of patients…”
Get full text

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial by Creutzberg, Carien L, van Putten, Wim LJ, Koper, Peter CM, Lybeert, Marnix LM, Jobsen, Jan J, Wárlám-Rodenhuis, Carla C, De Winter, Karin AJ, Lutgens, Ludy CHW, van den Bergh, Alfons CM, van de Steen-Banasik, Elzbieta, Beerman, Henk, van Lent, Mat

“…Postoperative radiotherapy for International Federation of Gynaecology and Obstetrics (FIGO) stage-1 endometrial carcinoma is a subject of controversy due to…”
Get full text

Dose Escalation and Quality of Life in Patients With Localized Prostate Cancer Treated With Radiotherapy: Long-Term Results of the Dutch Randomized Dose-Escalation Trial (CKTO 96-10 Trial) by Al-Mamgani, Abrahim, M.D, van Putten, Wim L.J., M.Sc, van der Wielen, Gerard J., M.D, Levendag, Peter C., M.D., Ph.D, Incrocci, Luca, M.D., Ph.D

“…Purpose To assess the impact of dose escalation of radiotherapy on quality of life (QoL) in prostate cancer patients. Patients and Methods Three hundred…”
Get full text

Dose–Volume Parameters of the Corpora Cavernosa Do Not Correlate With Erectile Dysfunction After External Beam Radiotherapy for Prostate Cancer: Results From a Dose–Escalation Trial by van der Wielen, Gerard J., M.D, Hoogeman, Mischa S., Ph.D, Dohle, Gert R., M.D., Ph.D, van Putten, Wim L.J., M.Sc, Incrocci, Luca, M.D., Ph.D

“…Purpose To analyze the correlation between dose-volume parameters of the corpora cavernosa and erectile dysfunction (ED) after external beam radiotherapy…”
Get full text